ZEALAND PHARMA/S (ZEAL) Given Consensus Rating of “Buy” by Brokerages
Shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) have earned an average rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $26.00.
ZEAL has been the topic of several research reports. ValuEngine upgraded shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, January 11th. Zacks Investment Research upgraded shares of ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, January 1st. TheStreet upgraded shares of ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th.
Shares of ZEAL traded down $0.02 during mid-day trading on Friday, hitting $18.28. The company had a trading volume of 1,562 shares, compared to its average volume of 11,835. ZEALAND PHARMA/S has a 1-year low of $11.51 and a 1-year high of $20.00. The stock has a market capitalization of $562.88 million, a PE ratio of 6.09 and a beta of 2.26.
An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. OLD Mission Capital LLC purchased a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 17,466 shares of the company’s stock, valued at approximately $203,000. OLD Mission Capital LLC owned about 0.06% of ZEALAND PHARMA/S at the end of the most recent quarter. 9.23% of the stock is owned by hedge funds and other institutional investors.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: Recession
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.